Author: Aurelija Kizalaitė Tittle: Tumor morphology and bones metastasis—correlation in metastatic breast carcinoma Purpose: Estimate the link between bones metastasis and tumor morphology (estrogen, progesterone, human epidermal growth factor2 receptor expression) in patients with metastatic breast cancer. Objectives: 1. To determine the prevalence of skeletal metastasis among patients with metastatic breast cancer. 2. To ascertain the connection between bone metastasis and hormones (estrogen and progesterone) receptors expression. 3. To ascertain the link between bones metastasis and HER2 receptors expression. Methods: Retrospective study of medical documentation of patients with metastatic breast cancer treated in the Hospital of Lithuan...
Objective: Bone metastases are common among patients with advanced breast cancer, putting patients a...
© 2018 Elsevier Ltd. Breast cancer is the most common cancer affecting women worldwide, with bone me...
Purpose: To identify patient populations at high risk for bone metastases at any time after diagnosi...
Objectives: To evaluate the pattern of skeletal metastases from breast carcinoma in an Asian popula...
BACKGROUND AND PURPOSE: It is widely recognized that tumor hormone receptor status correlates with o...
Abstract: Bone is the most preferred site for metastatic dissemination in breast cancer. The purpose...
Introduction: According to published statistics by the World Health Organization in 2011, cancer is ...
Zhenchong Xiong,1–3,* Guangzheng Deng,1–3,* Xinjian Huang,1–3,* Xing Li,1–3 ...
A systematic literature review was conducted to quantify populations of patients with primary breast...
Objectives:: To evaluate the pattern of skeletal metastases from breast carcinoma in an Asian popula...
Objective: Bone is the most common site of metastasis in breast cancer. Prognostic factors for predi...
Osteolytic bone metastases are common in breast cancer (BCa). Approximately, 70 % of patients dying ...
Abstract Bones are the most common metastatic site of re-lapse in breast cancer patients and the pre...
Bone metastases (BM) are still the main cause of morbidity in cancer patients because of skeletal-re...
BACKGROUND: In patients with metastatic breast cancer, the evaluation of the biological characte...
Objective: Bone metastases are common among patients with advanced breast cancer, putting patients a...
© 2018 Elsevier Ltd. Breast cancer is the most common cancer affecting women worldwide, with bone me...
Purpose: To identify patient populations at high risk for bone metastases at any time after diagnosi...
Objectives: To evaluate the pattern of skeletal metastases from breast carcinoma in an Asian popula...
BACKGROUND AND PURPOSE: It is widely recognized that tumor hormone receptor status correlates with o...
Abstract: Bone is the most preferred site for metastatic dissemination in breast cancer. The purpose...
Introduction: According to published statistics by the World Health Organization in 2011, cancer is ...
Zhenchong Xiong,1–3,* Guangzheng Deng,1–3,* Xinjian Huang,1–3,* Xing Li,1–3 ...
A systematic literature review was conducted to quantify populations of patients with primary breast...
Objectives:: To evaluate the pattern of skeletal metastases from breast carcinoma in an Asian popula...
Objective: Bone is the most common site of metastasis in breast cancer. Prognostic factors for predi...
Osteolytic bone metastases are common in breast cancer (BCa). Approximately, 70 % of patients dying ...
Abstract Bones are the most common metastatic site of re-lapse in breast cancer patients and the pre...
Bone metastases (BM) are still the main cause of morbidity in cancer patients because of skeletal-re...
BACKGROUND: In patients with metastatic breast cancer, the evaluation of the biological characte...
Objective: Bone metastases are common among patients with advanced breast cancer, putting patients a...
© 2018 Elsevier Ltd. Breast cancer is the most common cancer affecting women worldwide, with bone me...
Purpose: To identify patient populations at high risk for bone metastases at any time after diagnosi...